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ABSTRACT
Increased use of colistin therapy for infections
caused by Pseudomonas aeruginosa has indicated a
need for a more robust microbiological assay
technique. This report describes a quick and
simple microbiological assay for quantifying lev-
els of colistin sulphomethate in serum and urine
samples from cystic ﬁbrosis patients. The tech-
nique uses no specialised or costly equipment and
is suitable for use in all routine diagnostic
microbiology laboratories.
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Colistin, a multicomponent polypeptide com-
posed mainly of colistin A and B, is an effective
treatment of respiratory exacerbations caused by
Pseudomonas aeruginosa in cystic ﬁbrosis patients
[1]. Colistin is available as colistin sulphate, for
oral or topical use, and colistin sulphomethate
(CMS), for parenteral and inhalation therapy.
Both preparations are hydrolysed to a complex
mixture of partially sulphonated derivatives,
which possess varying antibacterial activities, as
well as colistin itself. Previously, intravenous use
of colistin was limited by concerns regarding
toxicity; however, with increased resistance to
other anti-pseudomonal drugs and the lower
toxicity of CMS, use of colistin is increasing. Early
therapy with inhaled CMS is now being used with
good effect to prevent deterioration in cystic
ﬁbrosis patients with chronic infection, and a
number of chronically infected cystic ﬁbrosis
patients have also been treated successfully with
3-month courses of intravenous CMS [1–3].
Although resistance to colistin is rare [4], reser-
vations exist concerning its nephrotoxicity and
neurotoxicity, and these limit its use to a certain
extent. However, reports of adverse reactions with
CMS are inconclusive, and attempts to correlate
toxicity with blood concentrations of CMS hinge
upon an accurate assay method for CMS.
The established microbiological bioassay for
colistin uses Bordetella bronchiseptica as the indi-
cator organism and Difco no. 10 agar (BBL,
Franklin Lakes, NJ, USA). This method is not
used widely because of a lack of sensitivity, the
inappropriateness of the indicator organism, and
difﬁculties in obtaining this agar [5]. High-
performance liquid chromatography assay meth-
ods for colistin have also been reported, but these
require specialised equipment and technical
expertise not present in many diagnostic labora-
tories [6]. In addition, there are issues concerning
the correct analysis and quantiﬁcation of colistin
because of the complex mixture of derivatives
obtained. In an attempt to address these prob-
lems, the present study reports the development
of a bioassay that uses an unremarkable clinical
isolate of Escherichia coli as the indicator organism.
The assay format used 100 mL of molten
Diagnostic Sensitivity Test (DST) agar (Oxoid,
Basingstoke, UK) supplemented with 130 mg of
p-aminobenzoic acid (Sigma, Poole, UK). This was
allowed to set in a sterile square 25 · 25 cm assay
plate. A 10-mL inoculum containing 107 CFU ⁄mL
of the E. coli indicator strain was applied to the
surface of the agar, which was then drained and
allowed to dry for 30 min. Powdered CMS (Forest
Laboratories, Bexley, UK) was dissolved in
sterile distilled water to a concentration of
1 g ⁄L, followed by dilution in pooled human
serum to concentrations ranging from 0.5 to
128 mg ⁄L. These standard concentrations were
added, with a positive meniscus, to 10-mm wells
cut in the agar. The samples were applied in
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triplicate, after which the plates were pre-incuba-
ted at room temperature for 4 h, and then at 37C
for 24 h. The zones of inhibition were then
measured and the mean zone diameters were
plotted against log concentration to produce a
standard curve [7].
The accuracy and precision of the method were
assessed by assaying triplicate samples, spiked
with known concentrations of CMS (Table 1), in
comparison with the standard curve. Over the
concentration range 0.5–43.0 mg ⁄L, the mean
accuracy was 93.7%, with an intra-assay precision
of 3.5–18.8%. These ﬁgures are similar to those
reported generally for other microbiological bio-
assays [8].
As CMS is known to undergo hydrolysis via a
complex pathway that includes active products,
the stability of serum samples spiked with known
concentrations of CMS was examined. In samples
stored at room temperature and at 4C, CMS was
stable for 7–10 days (< 10% change), after which
levels decreased at room temperature (66% loss
after 2 months), and increased slightly at 4C
(20% increase after 2 months). CMS was stable at
) 20C and at ) 40C for 21 days (< 10% change),
after which antibacterial activity increased (33%
increase after 2 months) as a result of hydrolysis
into the more potent derivatives. At ) 70C, CMS
was stable for the duration of the 2-month test
period. Therefore, it is advisable that samples for
CMS assay should be stored at ) 70C if the assay
is to be delayed by more than a few days.
In conclusion, the microbiological bioassay for
CMS described in this report is more accurate and
sensitive than themethodusedpreviously, andhas
been used for the past 3 years for the assay of
clinical samples. The bioassay can be used to assess
CMS concentrations in urine and serum samples
by comparison with standard concentrations of
8–128 mg ⁄L and 0.5–8 mg ⁄L, respectively. The
bioassay is less complex than high-performance
liquid chromatography methods, requires little
specialised equipment, and is ideally suited for
use in clinical microbiology laboratories.
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Table 1. Accuracy and precision of colistin bioassay
Test
Target value
(mg/L)
Mean valuea
(mg/L) %CV
1 30 27.8 16.8
2 27 30.9 17.7
3 12 15.5 18.8
4 26 21.3 10.6
5 27 28.6 19
6 29 34.0 5.5
7 43 45.0 3.5
8 0.5 0.6 6.2
9 0.75 0.7 9
10 0.8 0.77 11.2
11 0.9 1.02 4
%CV, percentage coefﬁcient of variation.
aMean value obtained following triplicate determinations.
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